2972-52-3Relevant articles and documents
Design, synthesis and evaluation of covalent inhibitors of DprE1 as antitubercular agents
Liu, Lingfeng,Kong, Chengcheng,Fumagalli, Marco,Savková, Karin,Xu, Yiwen,Huszár, Stanislav,Sammartino, José C.,Fan, Dongguang,Chiarelli, Laurent R.,Miku?ová, Katarína,Sun, Zhaogang,Qiao, Chunhua
, (2020)
Decaprenylphosphoryl-β-D-ribose 2′-oxidoreductase (DprE1) is a promising drug target for the development of novel anti-tubercular agents, and inhibitors of DprE1 are being investigated extensively. Among them, the 1,3-benzothiazinone compounds such as BTZ
MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR
-
Paragraph 001035, (2021/02/19)
This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), pharmaceutical compositions containing at least one such modulator, methods of treatment of cystic fibrosis using such modulators and pharmaceutical compositions, and processes for making such modulators.
JNK inhibitor as well as pharmaceutical composition and application thereof
-
Paragraph 0406-0409; 0428-0431, (2021/03/31)
The invention provides a compound represented by a formula (I), racemates, stereoisomers, tautomers, isotope markers, solvates, polymorphic substances, nitrogen oxides, or pharmaceutically acceptablesalts thereof, and application as a JNK inhibitor. The invention also provides a preparation method of the compound shown in the formula (I), a pharmaceutical composition containing the compound shownin the formula (I), and application of the compound shown in the formula (I) to preparation of a medicine, and the medicine is used for treating diseases which can be treated by inhibiting the activity of JNK.